Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

HCA raises 2026 guidance after strong Q3; analysts lift price targets

Oct 28, 2026, 9:48 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong beat on revenue and EPS plus raised 2026 guidance should lift investor confidence and possibly push the stock higher as consensus revises EBITDA multiples and earnings outlook upwards; similar historical moves occur when healthcare names beat and raise guidance amid stable macro conditions.

AI summary

What happened, with direct paths to the underlying reporting

HCA Healthcare posted a stronger-than-expected Q3 with revenue of $19.849B and adjusted EPS of $7.22, topping estimates. The company raised its FY2026 guidance for both earnings and sales, signaling durable profitability despite policy headwinds. The upbeat results, along with higher target prices from multiple banks, may support near-term upside and a re-rating of the stock.

Q3 revenue $19.849B, up 3.6% YoY, beat $19.332B est.
Adjusted EPS $7.22, vs $6.66 est; up from $6.96 prior year.
Guidance raised: FY2026 EPS $29.60-$30.50; revenue $78.25B-$79.50B.
Analysts lift targets: BAC $500, Baird $409, KeyBanc $490.
Stock closed at $449.96; positive tone amid policy headwinds.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.